Results 241 to 250 of about 53,302 (297)

Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure

Journal of Neurology, 2003
Recently, it was reported that botulinum toxin type B complex (BoNT/B) (NeuroBloc(R), Elan Pharmaceuticals) can produce an adequate therapeutic response in patients with antibody induced failure of botulinum toxin type A complex (BoNT/A) therapy. We wanted to study whether this effect is transient or sustained.
Dirk, Dressler, Hans, Bigalke, Reiner, Benecke   +2 more
openaire   +2 more sources

Early Postoperative Application of Botulinum Toxin Type A Prevents Hypertrophic Scarring after Epicanthoplasty: A Split-Face, Double-Blind, Randomized Trial.

Plastic and Reconstructive Surgery, 2019
BACKGROUND Postoperative hypertrophic scarring of the medial canthal area is a common phenomenon and deterrent for patients considering epicanthoplasty. Botulinum toxin type A has been reported for hypertrophic scar and keloid treatment.
Ru-Lin Huang, Chiakang Ho, M. Tremp, Yun Xie, Qingfeng Li, T. Zan   +5 more
semanticscholar   +1 more source

Extraoral Versus Intraoral Botulinum Toxin Type A Injection for Management of Temporomandibular Joint Disc Displacement With Reduction.

The Journal of craniofacial surgery (Print), 2019
: The present study was conducted to compare between extraoral and intraoral approach for botulinum toxin type A (BTX-A) injection into the lateral pterygoid muscle (LPM) in patients suffering from anterior disc displacement with reduction (ADDWR ...
A. A. Altaweel, Shadia A. Elsayed, A. Baiomy, S. E. Abdelsadek, AbdElKader Hyder   +4 more
semanticscholar   +1 more source

Botulinum toxin type A or selective neurotomy for treating focal spastic muscle overactivity?

Annals of Physical and Rehabilitation Medicine, 2019
OBJECTIVE To discuss the effectiveness, indications, limitations and side effects of botulinum toxin type A and selective neurotomy for treating focal spastic muscle overactivity to help clinicians choose the most appropriate treatment.
T. Deltombe, T. Lejeune, T. Gustin
semanticscholar   +1 more source

Purification of Clostridium botulinum type a toxin

Biochimica et Biophysica Acta (BBA) - Protein Structure, 1970
Abstract The neurotoxin of Clostridium botulinum Type A has been isolated and purified from a liquid culture. The toxin is homogeneuous by anion and cation exchange chromatography, gel filtration, isoelectric focusing and Ouchterlony gel diffusion technique. The specific toxicity of the purified toxin is 10 · 107 minimum lethal doses/1.0 A 278
B R, Dasgupta, L J, Berry, D A, Boroff
openaire   +2 more sources

The Use of Botulinum Toxin Type A in the Healing of Thyroidectomy Wounds: A Randomized, Prospective, Placebo-Controlled Study

Plastic and Reconstructive Surgery, 2019
Background: Recent research has indicated that botulinum toxin type A may have an inhibitory effect on the formation of fibroblasts and thus possibly decreases the severity of scar formation.
T. Phillips, Elaine Fung, M. Rigby, E. Burke, R. Hart, J. Trites, H. Gassner, S. M. Taylor   +7 more
semanticscholar   +1 more source

Treatment of Keloid Scars with Botulinum Toxin Type A versus Triamcinolone in an Athymic Nude Mouse Model

Plastic and Reconstructive Surgery, 2019
Background: Keloid scarring is a serious condition that mostly affects patients of African or Asian descent. Often disfiguring, this condition can have devastating psychosocial consequences. To date, no treatment modality has been proven ideal.
A. Fanous, A. Bezdjian, D. Caglar, A. Mlynarek, N. Fanous, S. Lenhart, S. Daniel   +6 more
semanticscholar   +1 more source

Different types of botulinum toxin in humans

Movement Disorders, 2004
In humans, botulinum neurotoxin (BoNT) serotype A (BoNT/A) is a useful therapeutic tool, but different BoNT serotypes may be useful when a specific immune resistance related to BoNT/A is proved. BoNT serotype F (BoNT/F) was injected into human muscles but its effects are shorter compared to BoNT/A, whereas BoNT serotype B (BoNT/B) is effective in ...
ELEOPRA R, TUGNOLI V, QUATRALE R, ROSSETTO, ORNELLA, MONTECUCCO, CESARE   +4 more
openaire   +2 more sources

Detoxification of Crystalline Botulinum Type A Toxin

The Journal of Immunology, 1947
Summary Botulinum Type A toxoid has been prepared from crystalline toxin by the addition of formaldehyde. The most active preparation consisted of one component electrophoretically, immunized mice in a dose containing 0.01γ of toxoidnitrogen and was 2400 times more active antigenically than crude toxoid on the basis of nitrogen-content.
G A, HOTTLE, A, ABRAMS
openaire   +2 more sources

Botulinum toxin type A in chronic migraine

Expert Review of Neurotherapeutics, 2007
The use of botulinum toxin type A continues to be investigated by the US FDA for potential use in the treatment of headache. As part of this process there has been extensive research conducted by individual study sites as well as multicenter trials. To date, the majority of the focus has been on migraine headache as well as on tension-type headache ...
openaire   +2 more sources